Literature DB >> 23278551

Adenosine and cAMP signalling skew human dendritic cell differentiation towards a tolerogenic phenotype with defective CD8(+) T-cell priming capacity.

John Challier1, Denis Bruniquel, Andrew K Sewell, Bruno Laugel.   

Abstract

Multiple endogenous mechanisms that regulate immune and inflammatory processes contribute to the maintenance of peripheral tolerance and prevent chronic inflammation in mammals. Yet pathogens and tumours are able to exploit these homeostatic pathways to foster immunosuppressive microenvironments and evade immune surveillance. The release of adenosine in the extracellular space contributes to these phenomena by exerting a broad range of immunomodulatory effects. Here we document the influence of adenosine receptor triggering on human dendritic cell differentiation and functions. We show that the expression of several immunomodulatory proteins and myeloid/monocytic lineage markers was affected by adenosine receptors and the cAMP pathway. These changes were reminiscent of the phenotype associated with tolerogenic dendritic cells and, functionally, translated into a defective capacity to prime CD8(+) T-cells with a common tumour antigen in vitro. These results establish a novel mechanism by which adenosine hampers CD8(+) T-cell immunity via dendritic cells that may contribute to peripheral tolerance as well as to the establishment of immunosuppressive microenvironments relevant to tumour biology.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23278551      PMCID: PMC3719950          DOI: 10.1111/imm.12053

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  49 in total

1.  Expression and function of adenosine receptors in human dendritic cells.

Authors:  E Panther; M Idzko; Y Herouy; H Rheinen; P J Gebicke-Haerter; U Mrowietz; S Dichmann; J Norgauer
Journal:  FASEB J       Date:  2001-09       Impact factor: 5.191

Review 2.  Tolerogenic dendritic cells.

Authors:  Ralph M Steinman; Daniel Hawiger; Michel C Nussenzweig
Journal:  Annu Rev Immunol       Date:  2001-12-19       Impact factor: 28.527

Review 3.  Dendritic cells: emerging pharmacological targets of immunosuppressive drugs.

Authors:  Holger Hackstein; Angus W Thomson
Journal:  Nat Rev Immunol       Date:  2004-01       Impact factor: 53.106

4.  Adenosine formation. Evidence for a direct biochemical link with energy metabolism.

Authors:  A C Newby; Y Worku; C A Holmquist
Journal:  Adv Myocardiol       Date:  1985

5.  Role of adenosine receptors in regulating chemotaxis and cytokine production of plasmacytoid dendritic cells.

Authors:  Max Schnurr; Tracey Toy; Amanda Shin; Gunther Hartmann; Simon Rothenfusser; Julia Soellner; Ian D Davis; Jonathan Cebon; Eugene Maraskovsky
Journal:  Blood       Date:  2003-10-09       Impact factor: 22.113

6.  Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase.

Authors:  David H Munn; Madhav D Sharma; Jeffrey R Lee; Kanchan G Jhaver; Theodore S Johnson; Derin B Keskin; Brendan Marshall; Phillip Chandler; Scott J Antonia; Russell Burgess; Craig L Slingluff; Andrew L Mellor
Journal:  Science       Date:  2002-09-13       Impact factor: 47.728

Review 7.  Immunoglobulin-like transcript 3: A crucial regulator of dendritic cell function.

Authors:  George Vlad; Chih-Chao Chang; Adriana I Colovai; Pasquale Berloco; Raffaello Cortesini; Nicole Suciu-Foca
Journal:  Hum Immunol       Date:  2009-03-09       Impact factor: 2.850

8.  Adenosine affects expression of membrane molecules, cytokine and chemokine release, and the T-cell stimulatory capacity of human dendritic cells.

Authors:  Elisabeth Panther; Silvia Corinti; Marco Idzko; Yared Herouy; Matthias Napp; Andrea la Sala; Giampiero Girolomoni; Johannes Norgauer
Journal:  Blood       Date:  2002-11-21       Impact factor: 22.113

Review 9.  Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors.

Authors:  Michail V Sitkovsky; Dmitriy Lukashev; Sergey Apasov; Hidefumi Kojima; Masahiro Koshiba; Charles Caldwell; Akio Ohta; Manfred Thiel
Journal:  Annu Rev Immunol       Date:  2004       Impact factor: 28.527

10.  Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.

Authors:  F Sallusto; A Lanzavecchia
Journal:  J Exp Med       Date:  1994-04-01       Impact factor: 14.307

View more
  28 in total

Review 1.  Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy.

Authors:  Jackie E Bader; Kelsey Voss; Jeffrey C Rathmell
Journal:  Mol Cell       Date:  2020-06-18       Impact factor: 17.970

Review 2.  Adenosine 2A receptors in acute kidney injury.

Authors:  I S Vincent; M D Okusa
Journal:  Acta Physiol (Oxf)       Date:  2015-05-19       Impact factor: 6.311

3.  Human monocytes respond to extracellular cAMP through A2A and A2B adenosine receptors.

Authors:  Ester Sciaraffia; Antonella Riccomi; Ragnar Lindstedt; Valentina Gesa; Elisa Cirelli; Mario Patrizio; Maria Teresa De Magistris; Silvia Vendetti
Journal:  J Leukoc Biol       Date:  2014-03-20       Impact factor: 4.962

Review 4.  Metabolites: deciphering the molecular language between DCs and their environment.

Authors:  Lucía Minarrieta; Peyman Ghorbani; Tim Sparwasser; Luciana Berod
Journal:  Semin Immunopathol       Date:  2016-12-05       Impact factor: 9.623

Review 5.  Role of dendritic cell metabolic reprogramming in tumor immune evasion.

Authors:  Michael P Plebanek; Michael Sturdivant; Nicholas C DeVito; Brent A Hanks
Journal:  Int Immunol       Date:  2020-06-26       Impact factor: 4.823

Review 6.  Targeting CD39 in cancer.

Authors:  Achim K Moesta; Xian-Yang Li; Mark J Smyth
Journal:  Nat Rev Immunol       Date:  2020-07-29       Impact factor: 53.106

7.  Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma.

Authors:  Donald T Weed; Paolo Serafini; Jennifer L Vella; Isildinha M Reis; Adriana C De la Fuente; Carmen Gomez; Zoukaa Sargi; Ronen Nazarian; Joseph Califano; Ivan Borrello
Journal:  Clin Cancer Res       Date:  2014-10-15       Impact factor: 12.531

8.  Down-Regulation of CD62L Shedding in T Cells by CD39+ Regulatory T Cells Leads to Defective Sensitization in Contact Hypersensitivity Reactions.

Authors:  Karsten Mahnke; Jurgina Useliene; Sabine Ring; Paula Kage; Verena Jendrossek; Simon C Robson; Matilda Bylaite-Bucinskiene; Kerstin Steinbrink; Alexander H Enk
Journal:  J Invest Dermatol       Date:  2016-09-10       Impact factor: 8.551

Review 9.  Myeloid cells in the tumor microenvironment: Role of adenosine.

Authors:  Silvana Morello; Aldo Pinto; Corrado Blandizzi; Luca Antonioli
Journal:  Oncoimmunology       Date:  2015-12-03       Impact factor: 8.110

Review 10.  The adenosine pathway in immuno-oncology.

Authors:  Bertrand Allard; David Allard; Laurence Buisseret; John Stagg
Journal:  Nat Rev Clin Oncol       Date:  2020-06-08       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.